Baxter International (BAX) Financials: History & Chart

Baxter International Inc. (BAX)BAXBaxter International Inc.

About Baxter International Inc.

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Deerfield, IL

37,500 employees

www.baxter.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Andrew Hider

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	11.32B	2.70B	2.97B	2.83B	2.81B	2.63B	2.75B	2.70B	2.69B
Cost of Goods Sold	7.91B	1.81B	2.40B	1.89B	1.82B	1.76B	1.79B	1.67B	1.66B
Gross Profit	3.41B	891.00M	577.00M	950.00M	991.00M	861.00M	959.00M	1.03B	1.03B
Gross Profit Margin	30.1%	33.0%	19.4%	33.5%	35.3%	32.8%	34.8%	38.3%	38.3%
Total Operating Expenses	3.71B	825.00M	1.31B	778.00M	800.00M	803.00M	1.39B	878.00M	852.00M
Research & Development	517.00M	139.00M	126.00M	118.00M	134.00M	140.00M	211.00M	129.00M	130.00M
Selling, General & Administrative	2.92B	728.00M	761.00M	708.00M	718.00M	703.00M	761.00M	754.00M	723.00M
Operating Income (EBIT)	-300.00M	66.00M	-729.00M	172.00M	191.00M	58.00M	-435.00M	155.00M	179.00M
Operating Margin	-2.7%	2.4%	-24.5%	6.1%	6.8%	2.2%	-15.8%	5.7%	6.6%
Income Before Tax (EBT)	-508.00M	-6.00M	-756.00M	121.00M	133.00M	-3.00M	-521.00M	69.00M	117.00M
Interest Income	47.00M	12.00M	11.00M	10.00M	14.00M	17.00M	10.00M	14.00M	18.00M
Interest Expense	287.00M	78.00M	69.00M	68.00M	72.00M	81.00M	100.00M	101.00M	104.00M
Other Income/Expense	-208.00M	-72.00M	-27.00M	-51.00M	-58.00M	-61.00M	-86.00M	-86.00M	-62.00M
Net Income	-1.10B	-15.00M	-1.13B	-46.00M	91.00M	126.00M	-512.00M	140.00M	-314.00M
Income Tax Expense	473.00M	11.00M	279.00M	172.00M	11.00M	-67.00M	-33.00M	8.00M	22.00M
Net Profit Margin	-9.7%	-0.6%	-37.9%	-1.6%	3.2%	4.8%	-18.6%	5.2%	-11.7%
EBITDA	671.00M	303.00M	-489.00M	409.00M	448.00M	305.00M	-190.00M	409.00M	406.00M
EBITDA Margin	5.9%	11.2%	-16.4%	14.4%	15.9%	11.6%	-6.9%	15.2%	15.1%
Depreciation & Amortization	971.00M	237.00M	240.00M	237.00M	257.00M	247.00M	245.00M	254.00M	227.00M
EPS Basic	-2.10	-0.03	-2.16	-0.09	0.18	0.25	-1.00	0.28	-0.61
EPS Diluted	-2.10	-0.03	-2.16	-0.09	0.18	0.25	-1.00	0.27	-0.61
Shares Outstanding	515.00M	515.00M	514.00M	514.00M	513.00M	512.00M	510.00M	510.00M	510.00M
Diluted Shares Outstanding	515.00M	515.00M	514.00M	514.00M	514.00M	514.00M	510.00M	512.00M	510.00M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	11.24B	10.64B	10.36B	10.06B	12.15B	11.67B	11.36B	11.10B
Cost of Goods Sold	7.87B	6.65B	6.21B	6.51B	7.43B	7.09B	6.60B	6.34B
Gross Profit	3.38B	3.98B	4.15B	3.55B	4.72B	4.59B	4.76B	4.76B
Gross Profit Margin	30.1%	37.5%	40.1%	35.3%	38.9%	39.3%	41.9%	42.9%
Total Operating Expenses	3.69B	3.97B	3.44B	6.39B	3.37B	2.97B	2.99B	3.17B
Research & Development	518.00M	590.00M	518.00M	450.00M	531.00M	521.00M	595.00M	654.00M
Selling, General & Administrative	2.89B	2.97B	2.95B	3.10B	2.85B	2.47B	2.54B	2.62B
Operating Income (EBIT)	-308.00M	14.00M	707.00M	-2.85B	1.35B	1.62B	1.77B	1.58B
Operating Margin	-2.7%	0.1%	6.8%	-28.3%	11.1%	13.8%	15.6%	14.3%
Income Before Tax (EBT)	-505.00M	-289.00M	242.00M	-3.25B	1.12B	1.29B	970.00M	1.62B
Interest Income	52.00M	67.00M	69.00M	19.00M	14.00M	19.00M	40.00M	48.00M
Interest Expense	290.00M	408.00M	508.00M	413.00M	207.00M	153.00M	111.00M	93.00M
Other Income/Expense	-197.00M	-303.00M	-465.00M	-403.00M	-234.00M	-324.00M	-802.00M	33.00M
Net Income	-957.00M	-649.00M	2.66B	-2.43B	1.28B	1.10B	1.00B	1.55B
Income Tax Expense	395.00M	37.00M	61.00M	-135.00M	83.00M	182.00M	-41.00M	65.00M
Net Profit Margin	-8.5%	-6.1%	25.6%	-24.2%	10.6%	9.4%	8.8%	13.9%
EBITDA	673.00M	1.01B	1.69B	-1.77B	2.22B	2.44B	2.56B	2.35B
EBITDA Margin	6.0%	9.5%	16.3%	-17.6%	18.3%	20.9%	22.5%	21.2%
Depreciation & Amortization	981.00M	997.00M	984.00M	1.07B	867.00M	823.00M	789.00M	771.00M
EPS Basic	-1.75	-1.27	5.25	-4.83	2.56	2.17	1.97	3.04
EPS Diluted	-1.75	-1.27	5.23	-4.83	2.53	2.13	1.93	2.97
Shares Outstanding	513.00M	510.00M	506.00M	504.00M	502.00M	509.00M	509.00M	534.00M
Diluted Shares Outstanding	513.00M	510.00M	506.00M	504.00M	508.00M	517.00M	519.00M	546.00M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.